Welcome to our dedicated page for Larimar Therapeutics SEC filings (Ticker: LRMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Larimar Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing nomlabofusp for Friedreich’s ataxia and other potential rare-disease programs using an intracellular delivery platform. Its 8-K reports disclose operating and financial results, FDA-related program updates, corporate presentations, material events and risk language around product development, regulatory review, capital needs and clinical execution.
The company’s SEC record also includes capital-structure and governance disclosures. Filings describe registered common stock on the Nasdaq Global Market, equity financing activity, an exchange involving Series A convertible preferred stock, preferred-stock conversion limitations, shareholder voting matters, executive compensation and board governance through proxy materials.
Larimar Therapeutics reported that an entity associated with Deerfield Management received a grant of stock options linked to 55,150 shares of common stock. The options have an exercise price of $3.33 per share and expire on May 19, 2036.
The option was granted to Jonathan S. Leff, who serves on Larimar’s board, but is held for the benefit and at the direction of Deerfield Management Company, L.P. It is scheduled to vest on the earlier of May 19, 2027 or the date of Larimar’s next annual stockholder meeting, subject to Leff’s continued board service. The reporting persons disclaim beneficial ownership beyond any indirect pecuniary interest.
Larimar Therapeutics, Inc. disclosed that an entity associated with director Jonathan S. Leff received a grant of stock options covering 55,150 shares of common stock. The options have an exercise price of $3.33 per share, expire on May 19, 2036, and were granted as compensation.
According to the disclosure, Leff, a partner in Deerfield Management Company, L.P., has no pecuniary interest in these options and disclaims beneficial ownership, holding them for the benefit and at the direction of Deerfield Management Company, L.P. The options vest on the earlier of May 19, 2027 or the company’s next annual stockholder meeting, subject to his continued service on the board.
Larimar Therapeutics director Jeffrey W. Sherman received a grant of 55,150 stock options for common stock. These options carry an exercise price of $3.33 per share and expire on May 19, 2036. They vest on the earlier of May 19, 2027 or the company’s next annual stockholder meeting, subject to his continued board service. This is a compensation-related award rather than an open-market trade, and no common shares were bought or sold in this filing.
Larimar Therapeutics, Inc. director Joseph Truitt reported receiving a stock option grant covering 55,150 shares of common stock. The option has an exercise price of $3.33 per share and expires on May 19, 2036.
These options vest on the earlier of May 19, 2027, or the date of Larimar’s next annual meeting of stockholders, in each case contingent on Truitt’s continued service on the Board of Directors. Following this grant, Truitt holds 55,150 stock options directly.
Larimar Therapeutics director Frank E. Thomas received a new stock option grant as equity compensation. He was awarded options to purchase 55,150 shares of common stock at an exercise price of $3.33 per share, with no cash paid at grant.
The options vest on the earlier of May 19, 2027 or the date of Larimar’s next annual stockholder meeting, in each case only if he continues serving on the board. Following this grant, he holds 55,150 stock options directly, highlighting a routine, service-based incentive award rather than an open-market trade.
Larimar Therapeutics director Thomas Edward Hamilton received a grant of stock options covering 55,150 shares of common stock. The options have an exercise price of $3.33 per share and expire on May 19, 2036. They vest on the earlier of May 19, 2027 or the company’s next annual stockholder meeting, subject to his continued service on the board. Following this grant, he holds 55,150 options directly.
Larimar Therapeutics, Inc. reported results of its 2026 annual stockholder meeting. As of the March 25, 2026 record date, 103,882,937 common shares were outstanding and entitled to vote.
Stockholders elected Frank Thomas, Carole S. Ben-Maimon, M.D., and Joseph Truitt as Class III directors, approved 2025 executive compensation on an advisory basis, and indicated a preference for holding future say-on-pay votes every year. The Board has decided to follow this annual frequency.
Stockholders ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026 and approved an amendment to increase authorized common shares from 115,000,000 to 215,000,000. They also approved a potential adjournment related to the share increase, although it was ultimately not needed.
Blue Owl Capital Holdings LP reported beneficial ownership of 10,739,492 shares of Larimar Therapeutics, Inc. common stock, representing 9.99% of the class. The position includes 7,120,007 shares of common stock, 975,700 shares issuable upon exercise of 9,757 call options, and 2,643,785 shares issuable upon conversion of Series A preferred stock. The reporting statement cites 103,882,937 shares outstanding as of March 17, 2026.
Larimar Therapeutics reported a net loss of $29.6 million for the quarter ended March 31 2026, similar to the prior year’s $29.3 million, as it continues to invest heavily in developing nomlabofusp for Friedreich’s ataxia.
Research and development expenses were $25.0 million and general and administrative costs were $6.1 million. Cash, cash equivalents and marketable securities rose to $200.4 million, helped by a February underwritten equity offering that generated net proceeds of about $107.6 million.
Larimar ended the quarter with an accumulated deficit of $464.4 million but believes its current cash can fund operations for at least twelve months. The FDA granted Breakthrough Therapy Designation to nomlabofusp, and the company plans a rolling BLA starting in June 2026, targeting a potential U.S. launch in the first half of 2027 if approved.
Larimar Therapeutics reported first quarter 2026 results while advancing nomlabofusp toward potential approval for Friedreich’s ataxia. The company held $200.4 million in cash, cash equivalents and marketable securities as of March 31, 2026, supporting a projected cash runway into the second quarter of 2027.
Larimar posted a first quarter 2026 net loss of $29.6 million, or $0.31 per common share, with research and development expenses of $25.0 million and general and administrative expenses of $6.1 million. A February underwritten equity offering raised net proceeds of $107.6 million, strengthening the balance sheet.
Regulatory momentum continued as the FDA granted Breakthrough Therapy Designation for nomlabofusp and reaffirmed willingness to consider skin frataxin levels as a surrogate endpoint. Larimar plans a rolling BLA beginning in June 2026 and expects to submit final modules, including CMC, in the second half of 2026, targeting a potential U.S. launch in the first half of 2027 if approved.